EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020)

Jennifer C Chan iD, Jonathan Dear iD, Carrie Palm iD, Krystle Reagan iD

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2023. Verfasst von Jennifer C Chan und 3 weiteren Autor:innen. Beteiligte Einrichtung: William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, California, USA. Hauptthemen laut MEDLINE: Mycoses, Acute Kidney Injury, Dog Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amphotericin-B (AmB) is an essential medication for the treatment of life-threatening systemic mycoses but the incidence and risk factors for acute kidney injury (AKI) after its administration are not known in dogs.

Objective

Determine the incidence of and risk factors for AKI in dogs receiving AmB. Animals Fifty-one client owned dogs receiving AmB for the treatment of systemic mycoses.

Methods

Retrospective study. Signalment, potential risk factors, AKI development (creatinine ≥0.3 mg/dL from baseline), drug formulation (deoxycholate [AmB-D] or lipid complex [ABLC]), dose, and treatment duration were recorded. The probability of an AKI diagnosis was evaluated using a log-rank test. The incidence of AKI and odds ratios were calculated for potential risk factors.

Results

Incidence of AKI was 5/12 (42%) for dogs receiving AmB-D and 14/39 (36%) for dogs receiving ABLC. Of the 19 dogs that developed AKI, 16 (84%) continued treatment after a pause in the planned dosing protocol. Fifty percent of dogs received a cumulative dose of 6.9 mg/kg for AmB-D and 22.5 mg/kg for ABLC (P < .01) at time of AKI diagnosis. ICU hospitalization (odds ratio [OR] 0.21, 95% confidence interval [CI]: 0.58-0.87) and inpatient status (OR 0.25, 95% CI: 0.07-0.86) were associated with decreased odds of AKI. Conclusions and Clinical Importance Incidence of AKI with AmB is common but does not always preclude continued treatment. The incidence of AKI is similar between AmB-D and ABLC, but dogs receiving ABLC tolerated a higher cumulative total dose before AKI diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MycosesAcute Kidney InjuryDog DiseasesDogsAnimalsAmphotericin BAntifungal AgentsRetrospective StudiesIncidence

Stichwörter der Autor:innen

aspergillosisfungalfungicidalnephrotoxicity

Substanzen

Amphotericin BAntifungal Agents

Autor:innen und Institutionen

  • William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, California, USA.
  • Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, California, USA.

ORCID-Profile: Jennifer C Chan, Jonathan Dear, Carrie Palm, Krystle Reagan

Zitieren

APA

Chan, J. C., Dear, J., Palm, C., & Reagan, K. (2023). Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020). Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16728

Vancouver

Chan JC, Dear J, Palm C, Reagan K. Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020). Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16728

BibTeX
@article{Chan2023,
  author = {Chan, Jennifer C and Dear, Jonathan and Palm, Carrie and Reagan, Krystle},
  title = {Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020)},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16728}
}
Kostenlos starten →